Article

Prognostic and predictive value ofTTF-1 expression in patients with recurrent or advanced lung adenocarcinoma without sensitizing EGFR mutations or ALK translocation treated with platinum-based chemotherapy

2023-12-12

Abstract excerpt

<title>Abstract</title> <p>Background Pemetrexed (PEM) is an effective treatment for adenocarcinoma of the lung. Thyroid transcription factor-1 (TTF-1) has been proposed as a predictive biomarker of cancer sensitivity to PEM. Methods We retrospectively screened 197 cases of recurrent or advanced lung adenocarcinoma without sensitizing epidermal growth factor receptor (<italic>EGFR</italic>) mutations or anaplas...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 85353456-c39d-5c74-b314-5c9aefb605a5
DOI: 10.21203/rs.3.rs-3667469/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prognostic and predictive value ofTTF-1 expression in patients with recurrent or advanced lung adenocarcinoma without sensitizing EGFR mutations or ALK translocation treated with platinum-based chemotherapyDOI 10.21203/rs.3.rs-3667469/v1Read

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.Semantic proximity Read

Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinomaSemantic proximity Read

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.Semantic proximity Read

The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.Semantic proximity Read

Thyroid transcription factor 1 (TTF-1) negativity as a predictor of unfavorable response to EGFR-TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations.Semantic proximity Read

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung AdenocarcinomasSemantic proximity Read

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).Semantic proximity Read

The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas.Semantic proximity Read

Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung AdenocarcinomaSemantic proximity Read

Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.Semantic proximity Read

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.Semantic proximity Read

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.Semantic proximity Read